Lilly sales inch up on demand for animal health, new drugs

Eli Lilly and Co. on Thursday reported better-than-expected second-quarter profit on a boost from its recently acquired animal health unit and raised its outlook. Revenue guidance was revised to $19.7 billion to $20.0 billion, up from $19.5 billion to $20.0 billion. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Leerink Swann increased their price target on Eli Lilly & Co from $77 to $92. The stock had a trading volume of 10,190,235 shares.

Eli Lilly and Company (NYSE:LLY) has received a buy rating for the short term, according to the rank of 2 from research firm, Zacks. On July 13, 2015 The shares registered one year high of $90.18 and one year low was seen on August 7, 2014 at $60.14. Eli Lilly’s revenues for Q2FY15 stood at $4.98 billion, representing a rise 0.81% YoY, as compared to revenues of $4.94 billion reported for the same period of FY 2014. Novartis AG (NVS)’S monthly performance stands at -.800% with an analyst rating of 1.8and dividend yield of 2.64%. On a weekly basis the shares of the shares have recorded a change of -1.32%.The block trade which occurred today had $11.78 million in upticks and $0 million in downticks with the up/down ratio climbing to 0. The ex-dividend date of this dividend is Wednesday, August 12th. Eli Lilly and presently has an average rating of Buy and an average price target of $86.61.

Looking at drug costs overall, the Lilly chief said, “We need an insurance system that provides adequate coverage for all the elements of care, including medicines that patients need”. The shares were sold at an average price of $82.39, for a total transaction of $17,301,900.00. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. The Companys new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab, , New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab.